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Abstract 
Neuroinflammation is recognised as one of the potential mechanisms mediating the 
onset of a broad range of psychiatric disorders and may contribute to non-
responsiveness to current therapies. Both preclinical and clinical studies have 
indicated that aberrant inflammatory responses can result in altered behavioral 
responses and cognitive deficits. In this review, we discuss the role of inflammation in 
the pathogenesis of neuropsychiatric disorders and ask the question if certain genetic 
copy number variants (CNVs) associated with psychiatric disorders, might play a role 
in modulating inflammation. Furthermore, we detail some of the potential treatment 
strategies for psychiatric disorders that may operate by altering inflammatory 
responses.  
 1. Introduction 
Neuropsychiatric disorders including devastating diseases such as schizophrenia, 
major depressive disorder and bipolar disorder are generally considered to have a 
multifactorial pathophysiology including both genetic and environmental factors [1]. 
Neuroinflammation may be one potential mechanism contributing to pathogenesis, 
anchored in the interplay of environmental factors such as hypoxia or infections and 
genetic susceptibility of the immune system.  
In fact, increasing amount of evidence suggests that inflammatory processes have an 
important role in the pathophysiology of psychiatric disorders. The significantly higher 
level of different inflammatory markers such as cytokines, chemokines and 
chemokine receptors in patients suffering from various form of psychiatric disorder 
has laid molecular foundation for the important role of inflammation in the 
pathogenesis of neuropsychiatric disorder [2-6]. Furthermore there is increasing 
evidence from genetic studies that these altered immune processes may play a 
primary role in the development of neuropsychiatric disorders, rather than simply 
being a consequence of brain disease.  Assuming inflammation plays a key role in 
the pathogenesis of psychiatric disorders, anti-inflammatory treatments may play a 
critical role in the treatment of these disorders. 
But to what extent and in which case has this anti-inflammatory therapy already been 
applied successfully? The efficacy of prescribing anti-inflammatory drugs to treat 
depression and other psychiatric diseases, either alone or in conjunction with 
traditional medication, remains to be elucidated. In this review, we will try to 
summarize the answers to these questions and sum up treatment recommendations 
where available. 
 
2. Relationship Between Inflammation and Mental Illness 
Recent studies on preclinical, genetics and bioinformatics data, have shown the 
activation of immune system molecules and pathways can contribute to pathogenesis 
of psychiatric disorders [7]. Several lines of the evidence that support a role for 
inflammation as a contributing factor in psychiatric disorders include: 
I. It has been established that cytokines that are found typically during an ongoing 
inflammatory process are found to be elevated in blood samples of patients with 
various types of psychiatric disorders. This, depending on the study, includes both 
generally considered pro-inflammatory (i.e. Interleukin (IL)-1-3, IL-5-9, IL-11-18, 
interferons (IFN), tumor necrosis factor (TNF), chemokines) as well as anti-
inflammatory (i.e. IL-4,-10,-11,-13) cytokines and complement factors. Though the 
activation cascade of this elevated cytokine production is not yet understood, the 
findings may point to a significant role of peripheral inflammatory processes in 
psychiatric conditions. Following examination of blood samples from patients with 
schizophrenia [8, 9], depression [10, 11], anxiety [12], bipolar disorder [13-15] 
obsessive-compulsive disorder (OCD) [16, 17], post-traumatic stress disorder (PTSD) 
[18, 19] and autism spectrum disorder [20, 21] significantly elevated levels of all 
major kinds of cytokines were detected. This also included soluble interleukin 
receptors, interleukin antagonists, TNF, soluble TNF receptor IFN-γ, chemokines and 
matrix metalloproteinases (MMP) (see Figure 1 and Table 1). The levels of some of 
these cytokines have also been correlated in some studies to the severity of disease 
symptoms [12, 17]. Work on the Whitehall II cohort shows that individuals with 
increased IL-6 levels over a prolonged period of time (one, two or three 
measurements over a 5 year period) have an elevated subsequent 10-year risk for 
development of cognitive symptoms of depression [22]. There are multiple studies 
showing elevated high sensitivity (hs-) C-reactive protein (CRP) levels in blood 
samples from patients with psychiatric disorders (schizophrenia, depression, PTSD, 
anxiety, autism). Elevated levels of pro-inflammatory cytokines like IL-6 and IL-1β 
can lead to the production of this acute phase protein in the liver [14, 23-28]. 
Importantly, a meta-analysis of 8 longitudinal studies showed that increased CRP 
levels are significantly associated with the risk for later development of depressive 
symptoms. This result was independent of age and a range of other risk factors of 
depression [24]. Interestingly, higher levels of CRP and IL-6 during childhood (age 
nine years old) were shown to be a predictor of higher risk of depression and 
psychosis in later life [29]. Increased CRP was even suggested as a diagnostic tool 
of autism spectrum disorder due to a positive correlation with symptom severity [27]. 
It is difficult to examine cytokine and acute phase protein levels in the brain directly 
and findings in the peripheral blood therefore have to be interpreted with caution. 
This is why it is worth looking, among other aspects, into gene expression when 
reviewing results from post-mortem samples of the brain. 
II. In schizophrenia, transcriptome analysis of brain tissue from autopsy of 
schizophrenic patients showed an increased expression of IFITM2, IFITM3, 
SERPINA3, and GBP1 was found. These genes are directly regulated by TNF-α, 
IFN-α and IFN-γ, suggesting a pro-inflammatory state [30]. A recent study examining 
gene expression of the dorsolateral prefrontal cortex from patients with mood 
disorders demonstrate an elevated expression of inflammatory agents (IL-1α, IL-2, 
IL-3, IL-5, IL-8, IL-9, IL-10, IL-12A, IL-13, IL-15, IL-18, IFN-γ, lymphotoxin-α) 
compared to control subjects [31]. Therefore, these results suggest that the findings 
seen using blood samples may be recapitulated in gene expression of key 
inflammatory agents in the brain, albeit in post-mortem samples. A systematic review 
of 119 publications on postmortem tissue investigating further evidence of 
inflammation in schizophrenia concluded that there is high variability between the 
results found in different studies. For astrocyte or microglia markers no consistent 
increase or decrease was found across different studies. These investigations varied 
in patient age, diagnosis, and brain region examined. Out of 33 studies, 6 showed an 
increase in the astrocyte marker, glia fibrillary acidic protein (GFAP), while 6 showed 
a decrease. An increase in microglial markers (CD68, human leukocyte antigen 
(HLA) antigens, MHC antigens, CD11b, Calprotectin, quinolinic acid) was found in 11 
studies and a decrease in 3 studies. In studies on general glia cell density, 7 of 34 
studies showed a decrease in glial cell density and 2 studies an increase. 
Furthermore, changes, mostly increases, in mRNA expression levels of chemokines 
and cytokines (interleukines, TNF-α, TNF-α receptor, IFN-γ) were frequently found in 
postmortem studies of schizophrenic brains. Other pro-inflammatory markers such as 
substance P, NF-κB, SERPINA3, interferon-induced transmembrane protein (IFITM) 
and others were found elevated in concentration and/or expression in certain brain 
regions in schizophrenia patients in some, though not all, studies [32]. A similar meta-
analysis of the literature on postmortems in mood disorders was somewhat more 
conclusive: in addition to findings of changes in the cytokine profile in the brain, it is 
argued that microglia and perivascular macrophages are found at increased density 
in the postmortem tissue. Meanwhile, oligodendroglia and GABAergic interneurons 
are found at a diminished number. One hypothesis that could explain this observation 
is that activated microglia release glutamate, which might damage neurons. The loss 
of oligodendroglia might also be a direct consequence of inflammation. So, pathways 
of neuroexcitation may be highly changed through neuroinflammatory mechanisms 
[33]. 
 
III. In multiple studies elevations of CRP and/or pro-inflammatory cytokine levels were 
shown to return to normal when the psychiatric disorder was treated. For example, 
the level of IL-1β and IL-2 in depression patients returned to a similar level to that 
seen in controls after treatment with serotonin reuptake inhibitors over a 20 week 
period [34]. Accordingly, bipolar disorder patients treated with mood stabilizers and 
antipsychotics responded with a significant decrease in high sensitivity CRP in the 
aforementioned study [14]. IL-1RA and IL-10 have also been found to be increased in 
drug-naïve schizophrenia patients decreased after 6 weeks of treatment with atypical 
antipsychotics. A strong correlation between IL-10 level and a score of negative, 
general and total symptoms was found. Plasma levels of IL-2 and IL-6 were found to 
be decreased after antipsychotic treatment of schizophrenic patients in a meta-
analysis of 8 similar studies [35]. Though little is said in the above studies on the 
correlation of patient outcome and the effects of pharmaceutics on cytokine levels, 
psychotherapy alone showed a decrease of IL-1Ra, IL-5,-6,-8,-10, G-CSF, IFN-γ, and 
TNF-α levels parallel to improvement of symptoms in major depression patients [36]. 
 
IV. There is increasing evidence that some primary genetic risk factors for psychiatric 
disorders impact on immune functions. Most common psychiatric disorders are highly 
polygenic. Genome-wide association analysis of 5 common psychiatric disorders 
including schizophrenia, bipolar disorder, depression, ADHD and autism identified 
genes in immune pathways as significantly contributing to risk [37]. The strongest 
and consistent association of SNPs for immune response and synaptic plasticity is 
associated with HLA region [38]. Recently, the most significant GWAS hit for 
schizophrenia risk (rs13194053), a SNP in the major histocompatibility complex 
region [39], was shown to exert risk in part by affecting through impacts on the gene 
encoding complement 4 (C4) [40]. Some rare but recurrent Copy Number Variants 
(CNVs) associated with mental illness also impact on immune functions, including the 
22q11.2 deletion associated with velo-cardio facial syndrome, a topic we will return to 
below. 
V. Conversely, patients with CNS inflammation caused by infection or brain injury can 
develop symptoms similar to those seen in psychiatric patients. In a study of 83 
patients with viral encephalitis 67% presented with psychomotor agitation, 55% with 
drowsiness, 47% with disorientation, 43% with visual hallucinations and 34% showed 
aggressiveness as a symptom. One year after hospital treatment in 70 of the same 
patients, 16% had memory disorders, 9% showed signs of aggressiveness, 8% 
suffered from aphasia, 8% from visual hallucinations, and 7% from auditory 
hallucinations [41]. Brucellosis, typhoid fever, Lyme disease, Leptospirosis and 
Whipple’s disease are all examples of inflammatory diseases caused by infection that 
can be accompanied by psychiatric symptoms ranging from depression, mania, 
personality trait and behavioral changes to manifest psychosis [42]. Regarding 
inflammation during healing after trauma, a survey of 722 outpatients after brain 
injury with an average of 10 days unconsciousness after injury found a rate of DSM-
IV valuable diagnosis of depression in 42% of patients [43]. Whilst it is not possible to 
fully dis-entangle the causal direction in these associations, they are consistent with 
the view that infection and brain injury may lead to psychiatric symptoms via the 
triggering of inflammatory processes. 
VI. Increasing number of studies support the hypothesis that autoantibodies that bind 
mainly to neuronal membrane protein or synaptic proteins results in psychiatric 
disorders. To date, the clear causative role of autoantibodies on psychotic symptoms 
has been most clearly shown for the N-methyl-D-aspartate receptor (NMDA-R), 
although further studies are still needed [44-46]. Similarly autoantibodies against 
dopamine-2 receptor, which regulates movement and behaviour has been associated 
with paediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infection and subjects with Tourette's syndrome [47]. Autoantibodies against anti-
opioid receptor, 5-hydroxytryptamine receptor 1A and muscarinic cholinergic receptor 
1 are thought to induce a depressive state in psychiatric illness [48, 49]. 
VII. Activation of inflammation in animal models lead to behavioral abnormlaities in a 
range of experiments. In rodent models, peripheral injection of inflammation-
provoking lipopolysaccharide (LPS - 0.83 mg/kg) has been shown to generate 
sickness/depression-like symptoms, i.e. prolonged period of immobility in forced 
swim test and tail suspension test. This effect was ascribed to an activation of the 
tryptophan-degrading enzyme indoleamine 2,3-dioxygenase [50]. Injecting animals 
with pro-inflammatory cytokines like IL-1a or TNF-α has also been shown to lead to 
sickness behavior in a dose- and time-related manner [51]. LPS injection to pregnant 
rats could be demonstrated to lead to pronounced changes of the offspring’s brain 
development: cortical and hippocampus thickness was found increased and markers 
for neural and glia progenitors decreased and abnormally distributed over the brain 
regions. This was accompanied by an inflammation reaction within the brain, as 
indicated by the elevated presence of cytokines [52]. It has been suggested that 
microglia activation through LPS-stimulation may lead to a damage of 
oligodendrocyte progenitor cells in a way that ultimately leads to severe losses of 
oligodendrocytes and myelination during development [53]. It is remarkable in this 
context, that immune system stimulating drugs like β-Interferon have been found to 
induce psychiatric symptoms, for instance in hepatitis C treatment [54, 55]. 
All the above points support the hypothesis that inflammation plays a significant role 
in the pathophysiology of major psychiatric disorders. However it remains unclear to 
what extent immune changes are primary in the causation of these conditions and to 
what extent they are a consequence of brain pathology. 
Finding pathways that can initiate neuroinflammation may help us find mechanistic 
key links between prolonged stress exposure or traumatic life events in relation to the 
development of a psychiatric disease. For instance, over-excitation of neurons in 
epilepsy has been demonstrated to activate microglia and inflammation [56]. If the 
same observation holds true for situations of sensory overload, experienced as stress 
and emotionally overwhelming feelings remains to be elucidated. Similarly, it is 
unclear if metabolic changes, like changes in circulation or hormone levels and 
receptors in straining situations lead to oxidative stress in the brain, which would in 
turn provoke neuroinflammation. 
The identification of the molecular mechanisms that connect inflammation and 
altered behavior will be important in the development of new treatments for 
neuropsychiatric disorders. Some emerging studies hypothesize that synaptic 
damage seen in psychiatric disorders may in part be a consequence of 
neuroinflammation, reflecting the situation seen in other conditions such as multiple 
sclerosis.Importantly, dysfunctional synaptic activity is associated with high activity of 
glutamatergic synapses and loss of GABAergic synapse function in schizophrenia 
and autism spectrum disorders. This imbalance seems to be provoked through 
cytokines that are upregulated during inflammation, very much like the ones we see 
in psychiatric disorders, supposedly released by activated microglia [57]. In most 
cases, inflammation within the CNS can activate an array of cellular and molecular 
changes including, activation of astrocytes, oligodendrocyte dysfunction, 
mitochondrial damage, changes in neurogenesis and neural circuits and a general 
imbalance of neurotransmitters with a surplus of dopaminergic and a loss of 
glutamatergic neurotransmission, it is also crucial for synaptic plasticity and pruning. 
Arguably, in concert these alterations can then lead to an impairment of behavioral 
functioning like cognition or emotion regulation [58]. 
 
3. Microglial pathology in Psychiatric disorders 
At a cellular level, microglia and astrocytes regulate the central nervous immune 
response. During the early embryonic brain development, microglia are the first glial 
cells to develop alongside neurons [59] and they constitute ≅10% of total glial cells in 
the adult brain [60]. Besides contributing to neuronal function [61, 62] microglia 
regulate the CNS response to antigens and inflammation [63], accompanied by 
cytokine and chemokine expression [64-67]. Following damage or stress, microglia 
located in intact areas elicit an immune response on the affected area by extending 
their processes. Microglial processes are highly dynamic and can sense the released 
ATP secreted from astrocytes and neurons in the damaged area [68]. Following 
activation microglia secrete two pro-inflammatory cytokines (IL-1β and TNFα), 
chemokines (CCL3, CCL5) and reactive oxygen/nitrogen species (nitric oxide, 
peroxides, superoxide, peroxynitrite) (Figure 1) [69-71]. In turn, this 
neuroinflammation may cause damage to neurons and other glial cells. Aging is 
another key factor that influences the status of microglial state and the associated 
inflammatory condition. The gene expression profile in the aged brain indicates a 
clear up regulation of immune-related genes, including enhanced expression of IL-
1β, TNFα and IL-6 [72], suggesting that age related changes also lead to enhanced 
activation of microglial cells and supposedly inflammation, in the absence of external 
damage. 
Besides being the first line of defense in the mammalian brain, microglia are 
important for synaptic formation and synaptic pruning [62, 73]. Microglia derived IL-
10 has been shown to promote synapse formation. Reduction in the level of microglia 
during the postnatal stage or young adult stage of development results in reduced 
spine formation in the motor cortex. This reduction in synapse formation is associated 
with reduced motor performance and reduced levels of synaptic proteins like GluN2B 
and vGlut1 [74]. These studies suggest that microglia are important for learning and 
memory by promoting learning associated synapse formation [75]. A recent study 
has demonstrated early life infection can lead to an increase in microglial derived IL-
1β level, which in turn modulates hippocampus dependent learning and memory [76]. 
This observation is further supported by animal studies, where neonatal bacterial 
infection of rats induces hippocampus-dependent memory deficits in adulthood [77]. 
Microglia also eliminate non-functional synapses through the fractalkine receptor 
(CX3CR1) in the hippocampus [78, 79]. In retinal ganglion cells they regulate pruning 
through the C3 complement pathway [80]. In a recent study it was noted that 
increased expression of the C4 gene, encoding complement 4, was associated with 
high risk of schizophrenia. With C4-deficient mice they have shown that C4 promotes 
C3 activation which targets subsets of synapse elimination by microglia, suggesting 
its involvement in synaptic pruning [40]. 
Furthermore, TGF-beta signaling has been demonstrated to regulate microglial 
mediated pruning [81]. Microglia also modulate the sleep-wake cycle through 
extraction and retraction of the process [82]. It has been hypothesized that the 
microglial circadian clock might play a causative role in cognitive deficits and 
depression [83]. Exposure to environmental factors, especially during development 
has been demonstrated to have profound effects on microglial state, inflammatory 
status of the brain as well as cognition [84-86]. Although the underlying mechanism 
behind this in the context of neuropsychiatric disorders is poorly understood, 
fractalkine signaling at least in part seems to mediate microglial response to 
environmental risk factors [87]. 
Given the important role that microglia play in normal brain development and 
neuronal homeostasis, it is not surprising their dysfunction leads to neuropsychiatric 
disorders. Recent postmortem studies and PET imaging of peripheral 
benzodiazepine receptors provide evidence for microglial activation in the brains of 
patients with neuropsychiatric disorders such as schizophrenia, depression, and 
autism [88-95]. In schizophrenia, a significant increase in microglial density along 
with signs of activation in prefrontal and visual cortex has been reported [96, 97]. 
These results are highly promising, even though more specific markers of microglial 
activation are still needed to confirm these findings. One possible candidate for that 
might be translocator protein 18 kDa (TSPO), as decreased radiotracing was 
associated with schizophrenia-like behavior and inflammatory cytokine elevation in a 
mouse model [98]. Furthermore, in animal models of Rett syndrome (RTT), a 
devastating neurodevelopmental disorder, which is caused by a mutation in the X-
linked MECP2 gene encoding methyl-CpG-binding protein 2, microglia release an 
abnormally high level of glutamate, causing excitotoxicity that may contribute to 
dendritic and synaptic abnormalities in RTT [99]. Furthermore, in Mecp2-null mice a 
reduced number of microglia, which fail to phagocytose debris as effectively as those 
in wild-type mice were found. These finding suggest that microglia may also be 
responsible for the disorder [100]. Stress-induced depressive-like condition in rodents 
has shown to be caused by reduced levels of microglia within the hippocampus and 
reduced expression of activation markers, which in turn might contribute to reduced 
hippocampal neurogenesis and increased depressive-like behavior [101]. Microglia 
expressing glucocorticoid receptors have also been shown to undergo extreme 
alterations when exposed to prolonged stress, like cell body shrinkage and debris 
accumulation in lysosomes [102].  
Sustained microglial activation has been shown to contribute to the alleviation of 
symptoms associated with neurological disorders including psychiatric disorders 
(Figure 1) [103]. Enhanced pro-inflammatory cytokine response in concert with 
microglia activation occurs in response to external immune challenges and has been 
associated with cognitive and behavioral deficits in rodents [104-106]. As described 
earlier, such associations between pro-inflammatory cytokine levels in blood and 
psychiatric disorders are numerous in humans. It is feasible that microglia, the most 
important pro-inflammatory secreting cells in the brain, might be responsible or at 
least involved in this increase in blood cytokine levels. It is interesting in this context 
that microglia also are very important postnatal development defining cells [107]. It is 
plausible to speculate that microglial state and functionality in the context of 
inflammation, may be altered in patients with a genetic susceptibility to psychiatric 
disorder tighter with environmental factors? With induced pluripotent stem cell based 
disease modeling, one way to further investigate this question would be to derive 
microglia with a known genetic high-risk profile for psychiatric disorders, which will 
help to understand the mechanisms and triggers involved behind pathological 
inflammation.  The potential mechanism of microglial activation that occurs during the 
course of psychiatric disorders is illustrated in Figure 1.  
 
4. High-risk Copy Number Variations (CNVs): A Link between genetic alteration, 
Psychiatric disorders and Inflammation? 
A strong association has been found between specific rare but recurrent 
chromosomal CNVs and psychiatric disorders, including schizophrenia, autism 
spectrum disorder, mood and anxiety disorders [108]. Microarray experiments have 
now revealed abundant copy-number variations, a type of genetic variations in which 
stretches of DNA are duplicated or deleted [109, 110]. These structural alterations 
can range from 1 kilobase to several megabases and include either a single gene or 
contiguous sets of genes resulting in hemzygious or triplicate genomic state. CNVs 
can control the underlying psychiatric phenotype in multiple ways. They can affect 
the gene expression level by gene dosage effects or act as a faulty regulatory 
element to gene transcription cascades affecting other gene loci. They can also lead 
to frame shifts resulting in an abnormal genetic fusion product [111]. The 
mechanisms by which CNVs can lead to neuropsychiatric disorders and underlying 
complex behavioural traits are perhaps most clearly shown by rare and highly 
penetrant CNVs, involving the loss, gain or disruption of a dosage-sensitive gene(s). 
Some of the most common CNVs associated with neuropsychiatric disorder include 
chromosomal region 1q21.1, 3q29, 15q11.2, 15q13.3, 16p11.2, 16p13.1 and 22q11 
[112]. The locus 1q21.1 is associated with duplications in autism and with deletions 
or duplications in mental retardation [113-115]. The 15q13.3 locus is associated with 
deletions in mental retardation with seizures, and deletions or duplications in autism 
and other neuropsychiatric disorders [116-118]. The most common microdeletion 
syndrome in humans, 22q11.2 results in an increased rate of a range of psychiatric 
disorders in children with other developmental and intellectual disabilities [119-122]. 
A 15q13.3 microdeletion in humans results in a range of 
neurodevelopmental/psychiatric disorders, including autism spectrum disorder, 
schizophrenia, epilepsy, and intellectual disability [116-118, 123-131]. 
Microduplication or deletion at the 16p11.2 loci is associated with schizophrenia, 
bipolar disorder, mental retardation, autism, seizure disorders, and psychosis in 
Alzheimer’s disease [132-135]. De novo CNV analysis has resulted in enrichment of 
genes that are associated with the NMDAR network, GABAA receptor, abnormal 
CNS synaptic transmission, abnormal learning/memory/conditioning, abnormal cued 
conditioning behaviour [112, 136-139]. However, these studies have not picked up 
genes that can influence inflammatory condition underlying psychiatric symptoms. 
 
There is strong evidence that deletions at 22q11.2 directly impact immune function. 
Thymic hypoplasia is a common feature associated with 22q11.2 deletions resulting 
in CD4+CD45RA+ T cell counts, which can result in immunodeficiency [140]. A recent 
study looking at a wide range of cytokines in patients with 22q11.2 deletions, 
demonstrates a significant increase in the serum levels of pro-inflammatory and 
angiostatic chemokine IP-10 in patients with 22q11.2 deletions compared to healthy 
individuals. The increased IP-10 profile was associated with conotruncal congenital 
heart defects [141]. It is less certain how these immune changes might relate to the 
psychiatric symptoms seen in the disorder, but a positive association between 
severity of autism-related behaviors and level of serum concentrations of 
inflammatory cytokines IL-1β, interferon gamma and IL-12p70 in individuals with 
22q11.2 deletions has been reported [142]. Furthermore, toddlers with 22q11.2 
deletion have an elevated level of CD3+, CD4+ and IL-4-IFN-γ+ lymphocytes as 
compared to healthy control, suggesting that 22q11.2 deletion is associated with 
dysregulated Th1 cytokine production such as IL-4 and IFN-γ [143]. However, if the 
dysregulated Th1 cytokine production is also present in adulthood needs to be 
investigated. A recent study looking at cellular modeling of neurodevelopment by 
differentiating of hiPSCs carrying 22q11.2 deletions into neuronal lineage reports a 
reduction in the level of neural differentiation propensity, neurite outgrowth and 
migration as compared to controls [144]. This phenotype was further associated with 
reduced expression level of miR-17/92 cluster and miR-106a/b cluster. A number of 
studies have established direct linkage of these clusters with dysregulated 
inflammation [145-147], suggesting that the underlying psychiatric symptoms 
associated with 22q11.2 deletions is at least in part associated with altered 
inflammatory state and the subjects are prone to an increased risk for a variety of 
autoimmune diseases [148]. 
TNF-α was found to be downregulated in expression in cells carrying the 15q13.3 
microdeletion. TNF-α is known as a potent activator of inflammation [149]. It is 
plausible to speculate that genes that are involved in the 15q13.3 duplication are 
capable of altering TNF-α expression leading to an altered inflammatory state of the 
central nervous system. The CHRNA7 gene is one of the genes in 15q13.3 deletions. 
It encodes the nicotinic acetylcholine receptor alpha 7 subunit (α7nAChR), which is 
associated with schizophrenia in clinical studies and rodent models. A recent study 
using immortalized lymphoblastoid cell lines with 15q13.3 homozygous deletion has 
shown the CHRNA7 gene to modulate the production of TNFα. Furthermore, they 
identified STAT3 as one of the four genes that are differentially expressed following 
15q13.3 deletions [149]. It has been demonstrated that STAT4 null mice showed 
impaired IL12-mediated functions [150]. IL-2 is an activator of the nitric oxide 
synthase [89], which has been demonstrated to be important for synaptic plasticity 
[151] suggesting that 15q13.3 deletion might modulate the synaptic plasticity through 
the STAT4/IL12/NOS pathway. 
 
5. Modulating Neuroinflammation to treat Psychiatric Disease 
5.1 Theories on pharmacological effects of anti-inflammatory drugs in 
psychiatric disorder 
A number of drugs with anti-inflammatory features have been investigated either 
retrospectively or prospectively in terms of potential impacts on psychiatric symptoms 
including Non Steroidal Anti-Inflammatory Drugs (NSAIDS) and the tetracycline 
related antibiotic minocycline. Aspirin, celecoxib and the NSAID group of anti-
inflammatory drugs, encompassing commonly prescribed drugs such as diclofenac, 
ibuprofen or indomethacin, work by blocking the immune cascade enzyme 
cyclooxygenase-COX[118], which result in reduced inflammation. COX is responsible 
for the translation of arachidonic acid into prostaglandins. COX-1, which is 
antagonized by classical NSAIDs, including diclofenac, ibuprofen and aspirin, is 
expressed ubiquitously in the body in addition to its role in inflammation. Celecoxib is 
a selective COX-2 inhibitor. COX-2 is mainly expressed during inflammation, but also 
in the brain and kidney [152]. In a rat model of neuroinflammation, created by 
injection of LPS, treatment with Celecoxib significantly decreased the rate of 
microglia and astrocyte co-activation together with levels of IL-1β. Dopaminergic 
neurons and astrocytes with an upregulation of COX-2 were found in diminished 
numbers in treated individuals as compared to controls [153]. Inhibition of COX-2 has 
also been shown to lead to decreased production of kynurenic acid, which is a 
glycine antagonist at the NMDA-receptor and a nicotinic receptor antagonist. It has 
been found in elevated concentrations in schizophrenia patients’ cerebrospinal fluid 
[154-156]. For minocycline, multiple effects seem to make up its anti-inflammatory 
character. In models of neuroinflammation, minocycline has been shown to inhibit 
activation and proliferation of microglia, as well as antagonizing important pro-
inflammatory enzymes like COX-2, iNOS, NAPDH-oxidase, and P38 MAPK. It also 
seems to reduce T-leukocyte migration to the CNS by inactivation of MMP-9 (the 
enzyme rendering the brain blood barrier permissive during inflammation).  
 In models of neurodegenerative disease, survival of neurons and glia cells can be 
increased through minocycline, through caspase dependent and independent 
mechanisms [157] (Figure 2). Little is known on why these drugs also work in 
psychiatric disorder, but one might speculate that the same cascades and factors of 
inflammation, notably microglia are affected. We have summarized the clinical trails 
of compounds that aim to reduce the pro-inflammatory mediators in psychiatric 
disorders (Table 2).  
 
5.2 Schizophrenia 
In schizophrenic patients, several clinical studies exist on adjunctive treatment with 
drugs with anti-inflammatory features.  
When 70 patients with at least a moderate symptom burden and a DSM-IV diagnosis 
for schizophrenia for under 10 years were treated with aspirin or placebo in addition 
to antipsychotic treatment, measurements by Positive and Negative Symptom Scale 
(PANSS) showed an improvement in overall psychopathology and in positive 
symptoms. However, no differences in negative symptom or general scores were 
found[158]. In a similar study add-on aspirin given to patients improved symptoms, 
however only in patients with high CRP serum levels [159]. In patients with an acute 
exacerbation of schizophrenia treatment with cyclooxygenase-2 inhibitor, celecoxib in 
addition to risperidone led to a significant improvement of positive and negative 
symptoms in excess of the relief assignable to the antipsychotic [154, 160-162]. On 
the other hand, when patients who had suffered from symptoms for at least three 
months despite treatment, rather than patients with an acute exacerbation of 
psychosis were treated with celecoxib in a similar study design, no difference in 
outcome was found [163]. So it might be that the effect of celecoxib add-on treatment 
in schizophrenia patients is dependent on the duration of the disorder. Looking at 
anti-inflammatory drugs as a possible risk or protective factor for psychiatric disorder, 
in a retrospective investigation looking at more than 2000 schizophrenic patients who 
had concomitantly taken non-steroidal anti-rheumatic drugs or paracetamol, 
researchers found a higher risk for relapse to active psychosis. It is not clear whether 
this may be simply assignable to the parallel comorbidity treated with non-steroidal 
anti-inflammatory drugs (NSAID) or the drug use per se [164]. Then again, previous 
NSAID use was examined in a case-control trial (82 cases, 359 controls) of 
antipsychotics prescription. This showed a significant reduction of risk to develop 
psychosis when NSAID had been taken, but only in male individuals [165]. A nested 
case-control study of 1443 case events indicating schizophrenia exacerbation in 
patients using antipsychotics looked back at recent use of COX-2 inhibitors. The risk 
for schizophrenia exacerbation was not increased when the anti-inflammatory drug 
had been taken beforehand (for 0-93 days) [166].   
  
Double-blind, randomized placebo controlled studies showed that adjunctive 
treatment with the tetracycline minocycline to usual treatment could significantly 
improve negative symptoms [156, 167, 168]. Though unchanged by the treatment 
with minocycline, positive symptom score seems to be predictor for that improvement 
of negative symptoms [169]. Furthermore, minocycline seems to have a positive 
effects on cognitive executive functions, i.e. working memory, cognitive shifting and 
planning [170]. A proportion of schizophrenic patient respond to Clozapine. In a 
recent study positive outcome along with improved cognitive outcome has been 
reported when patient received minocycline together with clozapine in a 10-week 
double-blind, placebo-controlled trial involving 52 patients [171]. So minocycline add-
on therapy seems especially interesting in negative and cognitive symptom treatment 
of schizophrenia. 
Although the above data are interesting, it can only reflect implication of inflammation 
in pathogenesis of schizophrenia. Therefore, randomised prospective trials with a 
larger sample size and longer follow-up duration are crucial to establish anti-
inflammatory therapy as an effective, safe, and tolerable add-on treatment in 
schizophrenia 
 
5.3 Bipolar disorder 
In bipolar disorder, investigations of pro-inflammatory cytokines, namely TNF-α, INF-
γ, IL-6 and high sensitivity CRP found elevated levels in a cohort of 30 patients in 
acute mania as compared to healthy controls. Most significantly, only levels of CRP 
were decreased after treatment with antipsychotic drugs (± electroconvulsive 
therapy) while patient showed good outcomes [14]. In a study originally aiming at the 
examination of a potential drug blocking effect of NSAID on treatment with mood-
stabilizers no difference in outcome for bipolar patients was found with and without 
NSAID [172].  
A trial on the effect of aspirin on lithium-using patients with erectile dysfunction found 
no differences in depressive or mania symptoms before and with the add-on 
treatment [173]. Nevertheless, aspirin had beneficial effects in a 
pharmacoepidemiological studys looking at mood stabilizer substance change or 
dosage increase in patients on lithium (interpreted as worsening of bipolar disorder) 
in correlation to the use of further drugs. Prescribed at a low-dose of 30 or 80 mg per 
day and for an unspecified time or for more than 1, 45, 90 or 180 days, the patients, 
picked from the nationwide Netherlands PHARMO Record Linkage System, had 
significantly less events of mood stabilizer treatment alteration [174]. 
In 2008 Nery et al, investigated the effect of celecoxib treatment in 28 patients with a 
DSM-IV diagnosis of bipolar disorder during a depressive or mixed episode of the 
disease. The study was randomized, double-blind and placebo-controlled and 
celecoxib was given out at a dosage of 400mg per day over 6 weeks. This was in 
addition to a stable treatment with mood stabilizers or atypical antipsychotics. Among 
the patients who finished the complete trial, a significant improvement of depressive 
symptoms (as measured by Hamilton Depression Rating Scale) could be found in the 
first week of celecoxib treatment [175]. Similarly, a study with celecoxib or placebo in 
46 patients, in addition to sodium valproate treatment showed that remission rates 
were significantly higher with the adjunctive treatment than without assessed by the 
young mania rating scale (YMRS) following treatment of 6 weeks. At day 42, YMRS 
scores were significantly lower in the celecoxib group [176]. Trials over multiple 
centres for treatment of psychiatric disease with add-on minocycline and/or 
celecoxib/aspirin are currently ongoing [177, 178]. 
The above adjunctive anti-inflammatory therapy has more efficacy and comparable 
tolerability compared with control, future prospective studies with a longer study 
duration which are based on larger sample sizes are needed to comprehensively 
evaluate the efficacy and tolerability of anti-inflammatory therapy in bipolar disorder. 
 
5.4 Major depression disorder 
Treatment of major depression with NSAID has been tried reluctantly so far because 
of reports in which parallel NSAID or COX-2 inhibitor treatment of comorbidity lead to 
supposed drug interaction and higher resistance level to antidepressant treatment 
[179]. However, there is a number of noteworthy, even if sometimes contradictory, 
clinical trials that frequently comes from investigations of anti-inflammatory 
comorbidity treatment. In a study on the effect of NSAID use in addition to 
escitalopram or nortriptyline treatment in a cohort of 811 major depression patients 
no significant effect of NSAID use on the outcome of the antidepressant therapy was 
found [180]. An Australian study in over 5000 men of older age (69-87 years) 
investigated the correlation between aspirin use and development of depressive 
symptoms. Individuals who had used aspirin as antiplatelet agent drug in the past, 
but had stopped the treatment before the mood assessment were at a significantly 
higher risk for higher scores of depression [181]. However, a population-based study 
of 1631 patients could not find any lower rates of depression in patients who had 
taken aspirin on a regular basis [182]. 
A meta-analysis of 4 randomized controlled trials with celecoxib adjunctive to 
treatment with antidepressants was able to show consistent improvements in 
depression scores, remission and response rate [183]. Similarly, in 52 outpatients 
with breast cancer and concomitant depression a trial compared outcome after 
treatment with diclofenac versus celecoxib. At the endpoint, both treatments showed 
significant improvement as indicated by HDSR score. The celecoxib treatment was 
significantly more successful than the diclofenac treatment, while the analgesic effect 
was comparable [184]. Patients with depression due to Brucellosis showed significant 
response to treatment with celecoxib (200 mg bid) as measured by Hamilton 
depression rating scale in a study on 40 patients over 8 weeks [185]. 
Then again, in the Alzheimer's Disease Anti-inflammatory Prevention Trial, a study in 
more than 2000 individuals older than 70 years and with a family history of 
Alzheimer’s disease (though without any cognitive dysfunction), the application of 
celecoxib or sodium naproxen was tested against placebo. In the beginning of the 
trial, around 20% of the test persons had an increased score for depression as 
measured by 30 item-Geriatric Depression Scale. However, there was no significant 
change in that percentage over the trial, or in scores of individual probands [186]. 
Thus, one could argue that the effect of celecoxib might be age-dependent. 
A 6 week open-label study in 25 inpatients with a DSM-IV diagnosis of major 
depression with psychotic features showed that minocycline (150mg/day) as 
adjunctive therapy to fluvoxamine, paroxetine or sertraline was beneficial. Both 
depressive and psychotic symptoms were significantly improved [187]. Similarly, HIV 
positive patients (n=46) with mild to moderate scores of depression (Hamilton 
Depression Rating Scale) were treated with 100 mg bid minocycline or placebo in a 
double-blind randomized trial. A significant reduction of depression score was 
observed by the end of six weeks [188]. 
 
5.5 Anxiety/ Anxiety disorder 
Even though to our knowledge there are no clinical trials with celecoxib, other NSAID 
or tetracyclines in anxiety disorder patients to date, there are some interesting 
observations on anti-inflammatory manipulation of the immune system in animal 
models of anxiety symptoms. One trial in experimental autoimmune encephalitis in a 
rat model of multiple sclerosis showed that gene treatment with IL-10 diminished 
anxiety and depression symptoms, indicated by voluntary wheel running frequency 
[189]. In mouse models of anxiety after traumatic brain injury [190] and of anxiety 
following neonatal immune activation by infection treatment with minocycline led to a 
significantly positive effect on psychopathologic outcome [191].  
A recent study provides evidence of high levels of IFN-γ and TNF-α, but low IL-10 
serum levels in anxiety patients when compared to healthy control subjects [192]. 
Furthermore, a large cohort study looking at the association between anxiety 
disorders and inflammation identified an elevated level of CRP in male patients with 
anxiety disorders [193]. In another study which included patients with rheumatoid 
arthritis receiving anti-TNF-α therapy had less frequent prevalence of any mood or 
anxiety disorders [194] demonstrating a beneficial role of anti-inflammatory therapy in 
anxiety disorders. Coumarin-derivate Esculetin [195] as well as phenolic rich Aronia 
metanocarpa berry juice attenuated anxiety and depressive symptoms in mice and 
rats, as measured during LPS-inducement and stress test, respectively. Both 
substances are known for their anti-oxidative power and it is thus feasible that the 
effect is assignable to an anti-inflammatory impact [196]. 
A synthetic derivative (4-phenylselenyl-7-chloroquinoline) with anti-inflammatory and 
anti-oxidative potential, was shown to have anxiolytic effects in mice, as measured by 
elevated-plus maze and light dark tests. The quinolone was applied 0.5 hours prior to 
onset and anxiety-related behaviour seemed avoided for up to 72h. However, the 
authors of this study assigned the effect primarily to a change in glutamate levels 
provoked by the drug rather than anti-inflammatory effect [197]. The polyphenol 
Honokiol is primarily known as a drug used in traditional Chinese medicine. In mice, 
application of honokiol (for 2 days at either 2 or 5 mg/kg i.p.) prior to induction of 
inflammation by LPS injection led to a decrease of anxiety levels, as measured by 
behavioural testing using the elevated plus maze and open field test. Furthermore, a 
significant decrease in plasma levels of IL-1β, IL-6, TNF-α and BDNF was found in 
those mice pre-treated with Honokiol as well as a liver-protective effect [198]. Of 
note, physical exertion is shown by several lines of evidence to have anti-
inflammatory effects and at the same time is one of the most effective non-
pharmaceutical remedies of anxiety [199]. 
  
 5.6 Obsessive-compulsive disorder 
In a double-blind randomized trial in 50 OCD outpatients, fluvoxamine in combination 
with anti-inflammatory COX-2 inhibitor celecoxib (200 mg bid) showed a significant 
improvement of symptoms in comparison with fluvoxamine alone and placebo control 
[200]. In a similarly designed study 48 OCD patients who were non-responders to 
serotonin reuptake inhibitors, were add-on treated with N-acetylcysteine (up to 2400 
mg/d) or placebo over 12 weeks. At the end of this period 15% more than in the 
placebo group were responsive to therapy in the N-acetylcysteine group (52.6%) 
[201]. 
In an open label study, 9 treatment-resistant outpatients with OCD were given 100 
mg/day of minocycline adjunctive to their treatment with serotonin reuptake inhibitors. 
In diagnostic testing by Yale–Brown Obsessive Compulsive Scale every 2 weeks 
over 12 weeks no significant improvements in outcome could be found in the cohort 
as a whole. However, in 2 patients with early-onset OCD, more than 30% reduction 
of the Yale–Brown Obsessive Compulsive Scale was reached, which was initially 
defined as a marker for treatment response [202]. Indeed, in a double-blind 
randomized trial on 102 OCD patients, therapy with minocycline (100 mg bid) as add-
on to fluvoxamine (100 mg/day for the first two days then 200 mg/day for the 
remaining 6 weeks of the trial) was associated with a significantly higher rate of 
patients responding completely or partially to the treatment. Measured by the Yale–
Brown Obsessive Compulsive Scale, total score and obsession subscale score were 
significantly lower in the minocycline than in the placebo group [203]. 
 
5.7 Autism spectrum disorder 
Little is found on anti-inflammatory treatment in autism spectrum disorder so far. Add-
on of celecoxib (up to 300 mg/day) to risperidone treatment in a study on 40 children 
suffering from autism lead to significant improvements of scores in irritability, social 
withdrawal, and stereotypy [204]. However, an open-label study in 11 children on 
treatment with 1.4 mg/kg body weight of minocycline found no clinical improvements 
after 6 months (measured using: Clinical Global Impression Severity Scale, Clinical 
Global Impression Severity Scale Improvement, Vineland Adaptive Behavior Scales). 
IL-8 was found significantly decreased in serum and cerebrospinal fluid, while other 
cytokines i.e. TNF-α, CD40L, IL-6, IFN-γ and IL-1β, were unchanged [205]. 
 
7. Conclusions 
A close examination of the literature demonstrates that the increased understanding 
of the microglia driven inflammatory effect on psychiatric diseases has not yet been 
translated into the clinical treatment for these disorders. The results from 
experimental animal models as well as from patients cohort studies are however 
quite promising. Adjunctive therapy with anti-inflammatory medication, especially in 
cases where conventional therapy has failed to bring complete recovery, may provide 
a novel route to treatment of these conditions. 
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 Figure 1: Potential mechanism of microglia activation in psychiatric disorders. 
Neuroinflammation, is one of the key components of the pathogenic mechanisms underlying 
several psychiatric disorders and is often associated with microglial activation/dysfunction. 
Accumulating evidence indicate that M1 like-microglia (proinflammatory) are significantly 
increased in comparison to ramified microglia (resting) and elongated M2-like microglia (anti-
inflammatory) phenotypes in disease states. The levels of M1-like microglia in brain 
predominate and potentially can be associated with the severity of the disease, suggesting 
an imbalance in M1/M2 phenotype. M1 like microglia are characterized by the expression of 
MHC class II antigens and by the production of pro-inflammatory cytokines and nitric oxide 
synthase (iNOS). Continued production of pro-inflammatory cytokines can lead to neuronal 
damage, astrogliosis, plasticity and cognitive decline. Peripherally derived macrophages and 
monocytes also participate in the inflammatory response. It is likely that during early stage of 
disease onset microglia can have phenotypic switch to an alternative state knows as M2-like 
phenotype, which are characterized by presence of surface markers like Arginase 1 and 
mannose receptor CD206, leading to resolution of inflammatory response by secretion of 
anti-inflammatory cytokines. The efficacy of the anti-inflammatory drug targeting M1/M2 
balance will significantly depend on therapeutic time window and severity of symptoms 
associated with the diseases.  
  
  
Figure 2: Pictorial diagram summarising the effects of anti-inflammatory 
medication on neuroinflammation mediated by microglia. Inflammation, amplified 
through the activation of microglia, leads to the release of cytokines, kynurenic acid, 
superoxides, lipid mediators, and matrixmetalloproteinases. These molecules may 
contribute to the pathological changes seen in neuropsychiatric conditions. Anti-
inflammatory drugs like cyclooxygenase inhibitors block the prostaglandin-mediated 
cascade of this inflammation. Minocycline acts via i) inhibiton of T-leucocyte 
migration over the blood-brain-barrier, ii) cytochrome c inhibition in mitochondria iii) 
antagonism of MAPK p38 and subsequent products iv) inhibition of COX-2 
(COX:Cyclooxigenase, MAPK: mitogen activated protein kinase) 
  
 Psychiatric disorder Cytokines / Acute phase proteins 
elevated 
Schizophrenia IL-1β, IL-6, IL12-p70, sIL-2R, TNF-α, 
IFN-γ [8, 9] 
Depression IL-1, IL-6, sIL-1R, sIL-2R, sIL-6, TNF-α, 
CRP [10, 11] 
Bipolar Disorder IL-4, IL-6, IL-10, sIL-2R, sIL-6R, TNF-α, 
sTNFR1, IL-1 receptor antagonist, INF-
γ, hs-CRP [13-15] 
Anxiety disorder IL-6, IL-8, IL-10, IL-18, MCP-1, MMP2, 
TNF-β [12] ⃰ 
OCD IL-2, IL-4, IL-6, IL-10, TNF-α, sTNFR1, 
sTNFR2 [16, 17] 
PTSD IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7, IL-8, IL-
10 and, IL12p40, IL12p70, IL-13, IL-15, 
TNF-α, MIP-1α, GM-CSF, IP-10, 
Eotaxin [18, 19] ⃰⃰ ⃰ 
Autism IL-1β, IL-1RA, IL-5, IL-8, IL12p40, IL-
12(p70), IL-13, IL-17 and GRO-α [20, 
21] 
Table 1: Circulating Cytokines and Acute Phase Proteins that are found elevated in 
different psychiatric disorders 
 ⃰ after stimulation with LPS 
 ⃰ ⃰ in PTSD and panic disorder patients 
  
Treatment 
 
Psychiat
ric 
disorder 
Probands Trial design Outcome Authors 
Aspirin 
1000 
mg/day 
plus 40 
mg/day 
pantopraz
ole, in 
addition to 
antipsych
otic 
treatment 
Schizoph
renia 
patients with at 
least moderate 
symptom burden 
and a DSM-IV 
diagnosis for 
schizophrenia 
spectrum disorder 
for under 10 years 
N=70 
Randomised 
controlled trial 
T=3 months 
mixed 
model 
improveme
nt in overall 
psychopath
ology and 
in positive 
symptoms 
as 
measured 
by PANSS,  
No 
differences 
in negative 
symptom or 
general 
scores 
Laan et al., 
2010 [158] 
Aspirin 
1000 
mg/day 
plus 40 
mg/day 
pantopraz
ole, in 
addition to 
antipsych
otic 
treatment 
Schizoph
renia 
Patients with 
moderate or above 
on CGI-Score, 
moderate score on 
two of PANSS 
items: delusions, 
hallucinatory 
behaviors, 
conceptual 
disorganization or 
suspiciousness/pe
rsecution, and/or a 
total PANSS 
negative 
symptoms score 
above 18 
N= 400 
Post-hoc 
analysis of 
randomised 
controlled trial 
T= 16 weeks 
Improveme
nts in 
patients 
with high 
CRP levels 
Weiser et 
al., 2014 
[159] 
Celecoxib 
200 mg 
bid in 
addition to 
2-6 
mg/day 
Risperido
ne 
 
Schizoph
renia 
Patients with acute 
exacerbation of 
schizophrenia 
N= 50 
Double blind, 
Randomised 
Placebo-
controlled 
T= 5 weeks 
Significant 
improveme
nt of 
positive 
symptoms 
Muller et 
al., 2002 
[206] 
 
Celecoxib 
in addition 
Schizoph
renia 
Patients with acute 
exacerbation of 
Open label, 
prospective, 
improveme
nt of 
Baheti et 
al., 2013 
to 
olanzapine 
schizophrenia 
N= 94 
controlled 
 
T= 6 weeks 
positive, 
negative 
and general 
psychopath
ology and 
total scores 
as 
measured 
by PANSS 
[161] 
Celecoxib 
(200 mg 
bid) in 
addition to 
risperidon
e (200 
mg/day) 
Schizoph
renia 
inpatients 
diagnosed with 
active phase 
schizophrenia 
N=60 
double-blind 
randomized 
placebo-
controlled 
T= 8 weeks 
significant 
improveme
nt 
regarding 
positive 
symptoms 
as 
measured 
by PANSS 
Akhondzad
eh et al., 
2007 [160] 
Celecoxib  Schizoph
renia 
Patients with a first 
manifestation of 
schizophrenia 
N= 49 
Double-blind 
randomised 
placebo-
controlled 
T= 6 weeks 
significant 
improveme
nt 
regarding 
positive 
and 
negative 
symptoms 
as 
measured 
by PANSS 
Muller et 
al., 2010 
[162] 
Celecoxib 
(400mg/da
y) in 
addition to 
antipsych
otic 
treatment 
Schizoph
renia 
Outpatients with 
symptoms and a 
DSM-IV diagnosis 
of schizophrenia, 
symptoms for at 
least three months 
despite treatment 
N= 38 
Double blind, 
randomized, 
placebo-
controlled, 
T= 8 weeks 
No 
difference 
in outcome, 
as 
measured 
by PANSS 
Rapaport et 
al. 2005 
[163] 
Concomita
nt intake 
of NSAID 
or 
paracetam
ol 
Schizoph
renia 
Schizophrenia 
patients 
N=2000 
Retrospective 
investigation 
higher risk 
for relapse 
to active 
psychosis 
Köhler et 
al., 2016 
[164] 
previous 
NSAID use 
Schizoph
renia 
Patients 
prescribed 
antipsychotics  
82 cases, 359 
case-control trial 
of antipsychotics 
prescription 
significant 
reduction of 
risk to 
develop 
psychosis 
Laan et al., 
2007 [165] 
controls when 
NSAID had 
been taken, 
but only in 
male 
individuals 
use of 
COX-
2inhibitors 
Schizoph
renia 
case events 
indicating 
schizophrenia 
exacerbation in 
patients using 
antipsychotics 
N=1443 
nested case-
control study 
 
T= previous 93 
days 
No 
increase of 
risk for 
schizophre
nia 
exacerbatio
n 
Stolk et al., 
2007 [166] 
Minocyclin
e in 
addition to 
usual 
treatment 
Schizoph
renia 
Patients with 
early-stage 
schizophrenia  
N=94 
Double-blind, 
randomised, 
placebo-
controlled 
T= 1 year 
Significant 
improveme
nt of 
negative 
symptoms 
as 
measured 
by PANSS 
Chaudhry 
et al., 2012 
[167] 
Minocyclin
e (200 
mg/day) in 
addition to 
risperidon
e 
Schizoph
renia 
patients with DSM-
IV diagnosis of 
early-phase (less 
than 5 years) 
schizophrenia who 
had been on a 
steady dosage of 
risperidone 
N= 93 
Double-blind, 
randomised, 
placebo-
controlled 
T= 16 weeks 
significant 
improveme
nt in 
treatment 
response in 
the Scale 
for the 
Assessmen
t of 
Negative 
Symptoms 
(SANS) 
total scores 
and 
PANSS 
scores for 
negative 
symptoms 
Liu et al., 
2014 [207] 
Minocyclin
e (200 
mg/day) 
Schizoph
renia 
patients with DSM-
IV diagnosis of 
schizophrenia, no 
treatment with 
therapeutics for 
one week before 
start of trial 
N= 43 
Randomised, 
placebo-
controlled 
T= 8 weeks 
Significant 
decrease of 
SANS 
score after 
8 weeks 
(though not 
4 weeks) of 
treatment 
Ghanizade
h et al., 
2014 [168] 
Minocyclin
e (up to 
200 
mg/day) in 
addition to 
risperidon
e (up to 6 
mg/day) 
Schizoph
renia 
Chronic 
schizophrenia 
patients 
N= 40 
Double-blind, 
randomised, 
placebo-
controlled 
T= 8 weeks 
Significant 
improveme
nt of 
negative 
symptom 
as 
measured 
by PANSS 
Khodaie-
Ardakani et 
al., 2014 
[169] 
Minocyclin
e 
Schizoph
renia 
Early-phase 
schizophrenia 
patients 
N= 54 
Double-blind, 
randomised,plac
ebo-controlled 
T= 6 months 
significant 
improveme
nt of 
negative 
symptoms 
and general 
outcome 
measured 
by PANSS, 
Clinical 
Global 
Impression 
(CGI) and 
insight 
score, 
improveme
nts of 
cognitive 
executive 
functions 
Levkovitz et 
al., 2009 
[170] 
NSAID and 
paracetam
ol 
Bipolar 
Disorder 
DSM-IV-TR 
diagnosis of 
Bipolar Disorder I 
or II and at least 
mild symptomatic 
N= 482 
secondary 
analysis from the 
Bipolar CHOICE 
study 
T= 6 months 
No 
difference 
as 
measured 
by CGI-BP 
Köhler et 
al., 2017 
[172] 
Aspirin Bipolar 
disorder 
Patients taking 
lithium with 
erectile 
dysfunction 
N= 32 
Double-blind, 
randomised, 
placebo-
controlled 
T= 6 weeks 
No 
differences 
in mania or 
depressive 
symptoms, 
significant 
improveme
nt of 
erectile 
dysfunction 
Saroukhani 
et al., 2013 
[173] 
Aspirin, 
low-dose 
of 30 or 80 
mg per 
day and 
Bipolar 
Disorder 
patients with at 
least five previous 
prescriptions for 
lithium and at least 
Pharmacoepide
miological study 
on the PHARMO 
Record Linkage 
System (RLS) in 
Significantl
y less 
events of 
mood 
stabilizer 
Stolk et al., 
2010 [174] 
for an 
unspecifie
d time or 
for more 
than 1, 45, 
90 or 180 
days, in 
addition to 
lithium 
1 year drug history 
N= 5145 
the Netherlands 
T= 10 year 
period 
treatment 
alteration 
Celecoxib 
(400 
mg/day) 
Bipolar 
Disorder 
DSM-IV diagnosis 
of bipolar disorder 
during a 
depressive or 
mixed episode of 
the disease 
N= 28 
Double-blind, 
randomised, 
placebo-
controlled 
T= 6 weeks 
improveme
nt of 
depressive 
symptoms 
(as 
measured 
by Hamilton 
Depression 
Rating 
Scale) 
found in the 
first week 
Nery et al., 
2008 [175] 
Celecoxib 
in addition 
to sodium 
valproate 
Bipolar 
Disorder 
Patients with 
diagnosis of acute 
bipolar mania with 
manic episode 
without psychotic 
features 
N= 46 
Double-blind, 
randomised, 
placebo-
controlled 
T= 6 weeks 
Significantl
y higher 
remission 
rates as 
measured 
by young 
mania 
rating scale 
Arabzadeh 
et al., 2015 
[176] 
Concomitt
ant NSAID 
use in 
addition to 
escitalopr
am or 
nortriptyli
ne 
Depressi
on 
Patients with 
major depression 
disorder treated in 
the GENDEP 
study 
N= 811 
Retrospective on 
the GENDEP 
study 
T= up to 12 
weeks 
No change 
of 
serotonine 
reuptake 
inhibitor 
treatment 
 
 
Uher et al., 
2012 [180] 
Previous 
aspirin 
use as 
anti-
platelet 
treatment 
Depressi
on 
men of older age 
(69-87 years) 
N= 5273 
Retrospective 
analysis of 
aspirin use after 
assessment of 
mood disorder 
symptoms 
T= last 5 years 
Significantl
y higher 
risk for 
depression 
in 
individuals 
who had 
used 
aspirin as 
antiplatelet 
agent drug 
in the past, 
Almeida et 
al., 2010 
[181] 
but had 
stopped the 
treatment 
before the 
mood 
assessmen
t 
(measured 
by Geriatric 
Depression 
scale) 
Regular 
aspirin or 
statin use 
in the past 
Depressi
on 
Depression 
patients 
N= 1631 
Population based 
study 
T= last 6 months 
No higher 
risk for 
developme
nt of 
depression 
Glaus et al., 
2015 [182] 
Celecoxib 
in addition 
to 
antidepres
sants 
Depressi
on 
Patients with 
depressive 
episodes 
N= 150 
meta-analysis of 
4 randomized 
controlled trials 
improveme
nts in 
Hamilton 
Rating 
Scale for 
Depression 
scores, 
remission 
and 
response 
rate 
Na et al., 
2014 [183] 
Diclofenac 
(50 mg 
bid) 
versus 
celecoxib 
(200 mg 
bid) 
Depressi
on 
outpatients with 
breast cancer and 
concomitant 
depression 
N= 52 
T= 6 weeks significant 
improveme
nts by 
HDSR 
score in 
both, 
celecoxib 
significantly 
more 
successful 
than 
diclofenac, 
analgesic 
effect 
comparable 
Mohammad
inejad et 
al., 2015 
[184] 
Celecoxib 
(200 mg 
bid) 
Depressi
on 
Patients with 
depression due to 
Brucellosis 
N= 40 
Double-blind, 
randomised, 
placebo-
controlled 
T= 8 weeks 
Significant 
improveme
nts on 
HDRS 
Jafari et al., 
2015 [185] 
celecoxib Depressi Individuals older Alzheimer's no Fields et 
(200 mg 
bid) or 
sodium 
naproxen 
(220 mg 
bid) 
on than 70 years and 
with a family 
history of 
Alzheimer’s 
disease (though 
without any 
cognitive 
dysfunction) 
N= 2312 
Disease Anti-
inflammatory 
Prevention Trial 
yearly follow-up 
 
significant 
change in 
individual 
or overall 
depression 
score 
measured 
by 30 item-
Geriatric 
Depression 
Scale 
al., 2012 
[186] 
Minocyclin
e (150mg/ 
day) as 
adjunctive 
therapy to 
fluvoxami
ne, 
paroxetine 
or 
sertraline 
Depressi
on 
inpatients with a 
DSM-IV diagnosis 
of major 
depression with 
psychotic features 
N= 25 
Open-label study 
T= 6 weeks 
Significant 
improveme
nt of 
depressive 
and 
psychotic 
symptoms 
as 
measured 
by Hamilton 
Depression 
Rating 
Scale and 
Brief 
Psychiatric 
Rating 
Scale 
Miyaoka et 
al., 2012 
[187] 
100 mg 
bid 
Minocyclin
e 
Depressi
on 
HIV positive 
patients with mild 
to moderate 
scores of 
depression 
N= 46 
Double-blind, 
randomised, 
placebo-
controlled 
T= 6 weeks 
significant 
reduction of 
depression 
score 
(Hamilton 
Depression 
Rating 
Scale) 
Emadi-
Kouchak et 
al., 2016 
[188] 
Celecoxib 
200 mg 
bid in 
addition to 
fluvoxami
ne  
OCD OCD outpatient 
N= 50 
Double-blind, 
randomised, 
placebo-
controlled 
T= 10 weeks 
Significant 
improveme
nt of 
symptoms 
Shalbafan 
et al., 2015 
[200] 
N-
Acetylcyst
ein (up to 
2400 
mg/day) 
 
OCD OCD patients, 
non-responsive to 
serotonin reuptake 
inhibitors 
N= 48 
Double-blind, 
randomised, 
placebo-
controlled 
T= 12weeks 
15% higher 
response 
rate 
Afshar et 
al., 2012 
[201] 
Minocyclin
e (100mg/ 
day) in 
addition to 
serotonine 
reuptake 
inhibitor 
OCD treatment-resistant 
outpatients with 
OCD 
N= 9 
Open-label study  
 
T= 12 weeks 
no 
significant 
improveme
nts in 
outcome in 
cohort as a 
whole, 
more than 
30% 
reduction of 
the Yale–
Brown 
Obsessive 
Compulsive 
Scale 
Rodriguez 
et al., 2010 
[202] 
Minocyclin
e (100 mg 
bid) as 
add-on to 
fluvoxami
ne (100 
mg/day for 
the first 
two 200 
mg/day for 
the 
remaining 
6 weeks of 
the trial) 
OCD OCD patients, 
N= 102 
Double-blind, 
randomized, 
placebo-
controlled 
 
T= 10 weeks 
significantly 
higher rate 
of patients 
responding 
completely 
or partially 
to 
treatment 
Yale–
Brown 
Obsessive 
Compulsive 
Scale, total 
score and 
obsession 
subscale 
score:signifi
cantly lower 
Esalatmane
sh et al., 
2016 [203] 
Celecoxib 
(up to 300 
mg/day) in 
addition to 
risperidon
e 
autism Children with 
autistic disorder 
N= 40 
Double-blind, 
randomized, 
placebo-
controlled 
 
T= 10 weeks 
significant 
improveme
nts of 
scores in 
irritability, 
social 
withdrawal, 
and 
stereotypy 
Asadabadi 
et al., 2013 
[204] 
Minocyclin
e (1.4 
mg/kg 
body 
weight) 
autism Children with 
autism spectrum 
disorder 
N= 11 
Open label 
 
T= 6 months 
no clinical 
improveme
nts (Clinical 
Global 
Impression 
Severity 
Scale, 
Clinical 
Pardo et 
al., 2013 
[205] 
Global 
Impression 
Severity 
Scale 
Improveme
nt, Vineland 
Adaptive 
Behavior 
Scales) 
Table 2: Clinical Studies on use of anti-inflammatory drugs in treatment of psychiatric 
disorder N: proband number, T: time frame, PANSS: positive and negative symptom 
score, SANS: Schedule for the Assessment of Negative Symptoms, CGI: clinical 
impression score 
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